The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from a randomized phase III study.
 
Anthony Selwyn Stein
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
Research Funding - Agios; Amgen; Celgene; Seagen; Stemline Therapeutics
 
Richard A. Larson
Consulting or Advisory Role - Amgen; ARIAD; Bristol-Myers Squibb; Celgene; CVS Caremark; Jazz Pharmaceuticals; Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Celgene (Inst); Daiichi Sankyo (Inst); ERYTECH Pharma (Inst)
 
Andre C. Schuh
Honoraria - Amgen; Celgene; Lundbeck; Novartis
Consulting or Advisory Role - Amgen; Celgene; Lundbeck; Novartis
Expert Testimony - Amgen; Lundbeck
 
William Stevenson
Honoraria - Amgen; Novartis
 
Ewa Lech-Maranda
Consulting or Advisory Role - Amgen
 
Kun Nie
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Zachary Franklin Zimmerman
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
William Kormany
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Max S. Topp
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Regeneron; Roche
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Roche